4.7 Article

Risk assessment for COVID-19 pandemic in Taiwan

Journal

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Volume 104, Issue -, Pages 746-751

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2021.01.042

Keywords

Risk assessment; Event-based surveillance; COVID-19; Emerging infectious disease; Public health

Ask authors/readers for more resources

Taiwan raised its COVID-19 risk level to "moderate-to-high" in mid-January 2020 when neighboring countries reported cases and human-to-human transmission became obvious. The risk level became "high" on January 24 due to China's escalating epidemic situation and lockdown in Wuhan. The importance of risk assessments and expert advice in making correct decisions early in a crisis was recognized.
Background and objectives: Event-based surveillance and rapid risk assessment for acute public health events are essential in emerging infectious disease control. Since detecting the unusual signal in Wuhan in December 2019, Taiwan has been aligning risk management to policy planning via conducting regular risk assessments to combat the coronavirus disease 2019 (COVID-19). This article aims to provide some insights into Taiwan's experiences and corresponding actions for the outbreak. Results: The COVID-19 risk level in Taiwan was raised to ?moderate-to-high? in mid-January 2020 when neighboring countries had reported cases and the human-to-human transmission became obvious. The risk level became ?high? on 24 January due to China's escalating epidemic situation and imposed a lockdown in Wuhan. We learned that the commander recognized the importance of risk assessments and considered advice from the experts was crucial in making the correct decision at the early stage of the crisis. Conclusions: Given the surge of COVID-19 cases globally, understanding the evidence-driven mobilizations via detailed risk assessments in Taiwan may be an example worth considering for other countries. We believe that strengthening a global epidemic intelligence network and sharing information in a timely and transparent manner are essential for confronting new challenges of COVID-19 and other emerging infectious diseases. ? 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available